Aim: This study was conducted to evaluate microbiological and clinical effects of a chitosan chlorhexidine (CH) mouthrinse on plaque control.
Materials And Methods: Subjects were divided into three groups. Group I included 15 subjects who used 0.2% chlorhexidine digluconate (CHX), group II included 15 subjects who used 2% chitosan (CH) solution, and group III involves 15 subjects who used 0.2% chlorhexidine/2% CH combination. Plaque index (PI), gingival index (GI), and probing depth (PD) were recorded at the baseline, on day 0, and after 4 days. Supragingival plaque samples were subjected for microbiological evaluation. Statistical analysis was done using statistical software IBM Statistical Package for the Social Sciences (SPSS), version 21.
Results: Plaque index was lowest in group I at day 0, while it was highest in group III. At day 4, PI was highest in group II, while lowest in group III. Gingival index was lowest in group I and highest in group II at day 0, and lowest in group I and highest in group III at day 4. There was no statistical difference in Streptococcus mutans (S. mutans) count between groups at any time interval.
Conclusion: Both chitosan and CH were found to be effective in controlling plaque. However, a combination of both provides even better results.
Clinical Significance: The present study showed that chitosan can be used as an antiplaque agent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5005/jp-journals-10024-2218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Metal-ligand cooperativity enables zero-valent metal transfer.
Chem Sci
January 2025
Department of Chemistry and Biochemistry, University of California Los Angeles California 90095-1569 USA
Group 13 aminoxy complexes of the form (L)E(TEMPO) (TEMPO = 2,2,6,6-tetramethylpiperidine 1-oxyl; L = THF (tetrahydrofuran) or Py (pyridine); E = Al, Ga, In) were prepared and structurally characterized. The complexes (THF)Ga(TEMPO) (1·THF) and (Py)In(TEMPO) (2·Py) are shown to heterolytically cleave H under mild conditions (3 atm, 20 °C, ≤ 1 h). 1·THF reacts reversibly with H to form a formal H-adduct that bears a Ga(iii) hydride site and a protonated TEMPO ligand with concomitant loss of THF, consistent with Ga(iii) and TEMPO functioning as Lewis acid and base, respectively.
View Article and Find Full Text PDFWater-Soluble Mn(III)-Porphyrins with High Relaxivity and Photosensitization.
Chem Biomed Imaging
January 2025
Department of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 3, CH-8093 Zürich, Switzerland.
Three water-soluble Mn(III)-porphyrin complexes with cationic pyridyl side groups bearing COOH- or OH-terminated carbon chains in the meta or para positions have been synthesized as probes for both magnetic resonance imaging (MRI) and photodynamic therapy (PDT). The complexes , , and are highly water-soluble, and their relaxivities range between 10 and 15 mM s, at 20-80 MHz and 298 K, 2-3 times higher than that of commercial Gd(III)-based agents. The complexes containing carboxylate () or alcoholic () side chains in the para position are endowed with higher relaxivities and have also shown efficient photoinduced DNA cleavage and singlet oxygen (O) generation.
View Article and Find Full Text PDFComparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review.
BMJ Oncol
February 2024
Division of Cancer Sciences, The University of Manchester, Manchester, UK.
Objective: To review the efficacy and safety of low-dose versus standard-dose enzalutamide, apalutamide or darolutamide treatment for metastatic prostate cancer.
Methods And Analysis: Keyword searches in MEDLINE and EMBASE up to 1 June 2023, with forward and backward citation searches of potentially relevant studies. Studies were included if primary outcome data were reported for patients with metastatic prostate cancer who had received reduced doses of enzalutamide, apalutamide or darolutamide.
Safety Evaluation of the Novel Cocktail of Monoclonal Antibodies for Postexposure Prophylaxis in Category III Animal Exposures.
J Glob Infect Dis
October 2024
Zydus Lifesciences Ltd., Ahmedabad, Gujarat, India.
Introduction: Rabies monoclonal antibody (mAb) is a life-saving immune-biological for postexposure prophylaxis (PEP) in all Category III animal exposures. A novel cocktail of mAbs derived using recombinant DNA technology is presently available for usage. The WHO recommends monitoring the clinical use and outcomes of mAb products.
View Article and Find Full Text PDFReporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors.
Future Sci OA
December 2025
Janssen Research & Development LLC, Raritan, NJ, USA.
Background: Including racial and ethnic minorities in clinical trials is essential for advancing health equity. Despite progress, trials often do not mirror patient population demographics.
Methods: The National Library of Medicine's Clinical Trials database was queried for phase III trials of lung, colorectal, breast, and prostate cancers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!